2024年V1/V2版《NCCN直肠癌临床实践指南》更新要点解读  

Interpretation of Updated NCCN Clinical Guidelines for Rectal Cancer(2024.V1/V2)

作　　者：曹沁涵 卓肖 夏雨菡 车杨曦 陈敏[1] CAO Qinhan;ZHUO Xiao;XIA Yuhan;CHE Yangxi;CHEN Min(Hospital of Chengdu University of Traditional Chinese Medicine/Clinical Medicine School of Chengdu University of Traditional Chinese Medicine,Chengdu 610072,China)

机构地区：[1]成都中医药大学附属医院/临床医学院,四川省成都市610072

出　　处：《中国全科医学》2025年第17期2070-2074,共5页Chinese General Practice

基　　金：国家自然科学基金面上项目(82274529);科研能力提升“百人计划”(20-B05)。

摘　　要：结直肠癌是消化系统中常见的恶性肿瘤之一,其发病率位居中国癌症发病率第二位。随着医学研究的深入和科技的进步,其诊疗策略也在不断演化。美国国家综合癌症网络(NCCN)紧跟科研前沿,分别于2024-01-29和2024-04-04发布了2024年V1/V2版《NCCN直肠癌临床实践指南》,这两次修订主要聚焦于分子学检测、免疫治疗、靶向治疗、新辅助治疗及疾病监测等方面的最新进展。本文通过分析2024年V1/V2版NCCN指南的更新要点,旨在为临床直肠癌的诊断与治疗实践提供更精确的参考依据。The incidence of colorectal cancer ranks second among cancers in China and colorectal cancer is also one of the most common malignant tumors in the digestive system.With the development of medical research and technology,the diagnostic and therapeutic strategies of colorectal cancer are continuously evolving.The National Comprehensive Cancer Network(NCCN)is closely following the forefront and released the 2024 V1/V2 versions of the NCCN Clinical Practice Guidelines for Rectal Cancer on January 29 and April 4,2024 respectively.The two revisions of the guidelines mainly focus on the latest research progress in molecular detection,immunotherapy,targeted therapy,neoadjuvant therapy and disease surveillance.This article analyzed the key updates of the 2024 V1/V2 NCCN guidelines,aiming to provide a more accurate reference for clinical rectal cancer diagnosis and treatment practice.

关 键 词：直肠肿瘤 基因突变检测 治疗策略 监测 美国国家综合癌症网络 指南解读 

分 类 号：R735.37[医药卫生—肿瘤]